Search Results

Summary This MAb reacts with the cellular as well as plasma form of fibronectin. Reportedly, after iv administration, this MAb localizes to tumor vessels where it binds to the underlying basement. Epitope recognized by this antibody is not accessible in normal tissues to the circulating MAb indicating that it can be used to specifically target tumor vessels in vivo. TV-1 is reportedly useful for delivering vasoactive agents to tumors to induce increased vascular permeability or blood flow prior to treatment with chemotherapeutic drugs or MAbs.

Summary This MAb recognizes full-length MUC1 in a glycosylation-independent manner and can bind to the fully glycosylated protein.The dominant epitope of this MAb is APDTR in the VNTR region. It reacts with the core peptide of the MUC1 protein, which is a member of a family of mucin glycoproteins that are characterized by high carbohydrate content, O-linked oligosaccharides, high molecular weight (200kDa) and an amino acid composition rich in serine, threonine, proline and glycine.

Summary This antibody is not expected to cross-react with SMAD1 and SMAD5.